Which factor has contributed to the reduction in high-grade CRS and ICANS over time?
Earlier intervention with agents like tocilizumab and steroids
Increased use of CD28 CAR constructs
Treating patients later in the disease course
Avoidance of inflammatory markers in risk assessment